Clinical trials
Colonic Neoplasms trials in Canada with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Terminated | 5 |
| Recruiting | 3 |
| Unknown status | 2 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Franco Carli | 2 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | 2 |
| Ottawa Hospital Research Institute | 2 |
| University Health Network, Toronto | 2 |
| University of Calgary | 2 |
| Canadian Cancer Trials Group | 1 |
| Christopher Andrews | 1 |
| Christopher Teshima | 1 |
| Hamilton Health Sciences Corporation | 1 |
| Indiana University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colonic Neoplasms | 23 |
| Inflammatory Bowel Diseases | 4 |
| Breast Neoplasms | 3 |
| Colonic Polyps | 3 |
| Colorectal Neoplasms | 3 |
| Neoplasms | 3 |
| Prostatic Neoplasms | 3 |
| Diverticulitis | 2 |
| Lung Neoplasms | 2 |
| Adenoma | 1 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.